
    
      This exploratory single center, open-label, single treatment group assignment, safety and
      efficacy study will enroll 15 patients with severe IgA nephropathy. Subjects will receive 1
      cycle of VelcadeÂ® to induce clinical remission. Follow-up visits will occur monthly for a
      year.

      For this pilot study, the proportion of patients with clinical remission or partial response
      will be analyzed.
    
  